Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Gandara on Practice-Changing Studies in Lung Cancer

October 13th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, a 2017 Giant of Cancer Care in Lung Cancer®, discusses practice-changing studies in lung cancer.

Nivolumab Misses OS Endpoint in SCLC Study

October 12th 2018

Single-agent nivolumab (Opdivo) did not improve overall survival compared with standard topotecan or amrubicin, where approved, in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.

Lead Investigator Discusses Frontline Pembrolizumab in NSCLC

October 12th 2018

Gilberto Lopes, MD, discusses the KEYNOTE-042 results and ongoing developments with immunotherapy in NSCLC.

Dr. Borghaei on Molecular Profiling in Lung Cancer

October 12th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses molecular profiling in lung cancer.

Dr. Forster on Next Steps With Lurbinectedin in SCLC

October 11th 2018

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).

Dr. Papadimitrakopoulou on Biomarker-Driven Clinical Trials in NSCLC

October 11th 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer.

Dr. Garon Discusses Driver Mutations in SCLC

October 10th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses driver mutations in small cell lung cancer.

Immunotherapy in NSCLC: Audience Q&A

October 10th 2018

I-O Therapy Versus Surgery or Chemotherapy in NSCLC

October 10th 2018

PD-L1 Expression in NSCLC

October 10th 2018

Managing Pneumonitis in NSCLC

October 10th 2018

Immunotherapy in Locally Advanced NSCLC

October 10th 2018

Experience With I-O Therapies in Second-Line NSCLC

October 10th 2018

Continuing/Re-Challenging With I-O Therapy in NSCLC

October 10th 2018

Treating Relapsed/Refractory NSCLC After I-O Therapy

October 10th 2018

TMB as a Predictive Biomarker in NSCLC

October 10th 2018

Combining Chemotherapy & Immunotherapy in Squamous NSCLC

October 10th 2018

Immunotherapy + Chemotherapy in Nonsquamous NSCLC

October 10th 2018

Upfront PD-1 Inhibitor Monotherapy in Advanced NSCLC

October 10th 2018

Practical Application of Recent Clinical Data for Immunotherapy in NSCLC

October 10th 2018